Skip to content
← All treatment topics

TREATMENT READING

Childhood Breast Tumors

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

For patients

Treatment of breast lumps in children

Source: Breast Lumps and Breast Cancer in Children, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

Treatment of breast lumps in children

There are different types of treatment for children and adolescents with benign breast lumps. You and your child's care team will work together to decide treatment.

Treatment of breast lumps in children and adolescents may include:

Watchful waiting, which is closely monitoring a person's condition without giving any treatment until symptoms appear or change. Watchful waiting may be done for fibroadenomas because they may disappear without treatment.

Surgery to remove fibroadenomas that have not disappeared or phyllodes tumors. The whole breast is not removed during surgery. Surgery may also be used for lumps that come back.

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Childhood Benign Breast Tumors (Fibroadenoma and Phyllodes)

Treatment of Fibroadenoma and Phyllodes Tumors

Source: Childhood Breast Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 11, 2024. Captured 2026-09-09.

Treatment options for fibroadenoma include the following:

Observation.

Sources: Observation

Surgery.

Sources: Surgery

Health professional · Childhood Benign Breast Tumors (Fibroadenoma and Phyllodes) / Treatment of Fibroadenoma and Phyllodes Tumors

Observation

Source: Childhood Breast Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 11, 2024. Captured 2026-09-09.

Evidence (observation):

A study of 29 patients with presumed fibroadenomas were diagnosed prospectively over a 13-month period via physical examination.[7]

Sources: 7

A study of 29 patients with presumed fibroadenomas were diagnosed prospectively over a 13-month period via physical examination.[7]

Nine presumed fibroadenomas (31%) resolved during the follow-up period of 1 to 12 months, and four presumed fibroadenomas (14%) became smaller.

Twelve teenagers underwent ultrasonography and had solid masses. None of these masses resolved after a year of observation. In addition, resection determined that all of these masses were fibroadenomas.

There is no evidence that childhood or adolescent fibroadenomas have carcinomatous potential.

Health professional · Childhood Benign Breast Tumors (Fibroadenoma and Phyllodes) / Treatment of Fibroadenoma and Phyllodes Tumors

Surgery

Source: Childhood Breast Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 11, 2024. Captured 2026-09-09.

Indications for resection include tumor size at presentation of 2 cm to 5 cm (or larger); tumor enlargement during 2 to 12 months of observation; multiple breast masses or bilateral breast masses; and patient, parental, or provider anxiety.[1,2]

Sources: 1 · 2

Evidence (surgery):

In one series of 39 patients with fibroadenomas who had follow-up after resection, the following was observed:[3]

Sources: 3

In one series of 39 patients with fibroadenomas who had follow-up after resection, the following was observed:[3]

Six patients experienced recurrences between 2 years and 7.5 years (median, 4.9 years) later.

Tumor size, mitotic index, and mesenchymal cellularity did not predict recurrences, and all recurrent tumors were benign.

Surgical complications have included breast hypoplasia, acute pain, and chronic pain.[8]

Sources: 8

While recurrence is rare, careful follow-up monitoring is important. Recurrent tumors can be resected successfully using conservative techniques.[8]

Sources: 8

Treatment options for phyllodes tumors include the following:

Surgery.

Sources: Surgery

Health professional · Childhood Benign Breast Tumors (Fibroadenoma and Phyllodes) / Treatment of Fibroadenoma and Phyllodes Tumors

Surgery (wide local excision without mastectomy)

Source: Childhood Breast Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 11, 2024. Captured 2026-09-09.

Phyllodes tumors can be very large and challenging to treat surgically in women with smaller breasts. Complete excision of the phyllodes tumor with grossly negative margins and a small amount of normal tissue circumferentially is necessary. Radical mastectomy or modified radical mastectomy should be avoided. Lymph node evaluation is not necessary.[9]

Sources: 9

Phyllodes tumors present a small risk of recurrence, as they fall into the intermediate-grade sarcoma category. These tumors do not metastasize, but they can recur locally.

Health professional

Special Considerations for the Treatment of Children With Cancer

Source: Childhood Breast Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 11, 2024. Captured 2026-09-09.

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

Sources: 1

Primary care physicians.

Pediatric surgeons.

Pathologists.

Pediatric radiation oncologists.

Pediatric medical oncologists and hematologists.

Ophthalmologists.

Rehabilitation specialists.

Pediatric oncology nurses.

Social workers.

Child-life professionals.

Psychologists.

Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

Sources: Supportive and Palliative Care

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: 2 · NCI website

Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Sources: 3 · 5 · Late Effects of Treatment for Childhood Cancer

Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.

Sources: 6 · Rare Diseases Act of 2002

The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:

Sources: 7 · 8

A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]

Sources: 9

The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.

Sources: 10 · 4

These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.

Information about these tumors may also be found in sources relevant to adults with cancer, such as Breast Cancer Treatment.

Sources: Breast Cancer Treatment

Health professional · Childhood Breast Cancer

Treatment of Breast Cancer in Adolescents and Young Adults (AYA)

Source: Childhood Breast Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 11, 2024. Captured 2026-09-09.

Breast cancer is the most frequently diagnosed cancer among AYA women aged 15 to 39 years, accounting for about 14% of all AYA cancer diagnoses.[16] Breast cancer in this age group has a more aggressive course and worse outcome than in older women. Expression of hormone receptors for estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) on breast cancer in the AYA group is also different from that in older women and correlates with a worse prognosis.[8,17]

Sources: 16 · 8 · 17

In a review of data from the National Cancer Database, AYA patients (aged 15–39 years) had a higher incidence of triple-negative breast cancer (TNBC) or HER2-positive (HER2+) cancer than did adult patients (TNBC: 21.2% vs. 13.8%, respectively; HER2+: 26.0% vs. 18.6%, respectively; both P < .001). In addition, patients aged 15 to 29 years had more advanced disease and TNBC or HER2+ disease than did patients aged 30 to 39 years.[18][Level of evidence C1]

Sources: 18 · Level of evidence C1

Treatment of AYA patients is similar to that of older women. However, unique aspects of management include attention to genetic implications (i.e., familial breast cancer syndromes) and fertility.[19,20]

Sources: 19 · 20

For more information, see Breast Cancer Treatment and Genetics of Breast and Gynecologic Cancers.

Sources: Breast Cancer Treatment · Genetics of Breast and Gynecologic Cancers

Health professional · Childhood Breast Cancer

Treatment Options Under Clinical Evaluation for Childhood and AYA Breast Cancer

Source: Childhood Breast Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 11, 2024. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

NCT05879926 (Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression Plus Hormonal Therapy in Premenopausal Estrogen Receptor (ER)–Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning [OFSET Trial]): This phase III trial will determine whether adjuvant chemotherapy added to ovarian function suppression and endocrine therapy improves invasive breast cancer–free survival among premenopausal, early-stage breast cancer patients (aged 18 years and older) with ER-positive, HER2-negative tumors and a 21-gene recurrence score between 16 and 25 (for pN0 patients) or 0 and 25 (for pN1 patients).

Sources: NCT05879926

Studies

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NCT05879926 · RECRUITING · phase3

Breast Cancer

ClinicalTrials.gov record

Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer

NCT03435380 · COMPLETED · na

Breast Neoplasms, Early Detection of Cancer

ClinicalTrials.gov record

Disease and treatment settings

Childhood Breast Tumors

Disease and treatment setting

Breast Tumors in children and adolescents